Abstract U.S. GRAS status is an important safety milestone, but it does not authorize an ingredient for sale in Canada. Instead, Health Canada evaluates ingredients under its own regulatory framework, […] Read More >>
As GLP-1 receptor agonist drugs like Ozempic®, Wegovy®, and Mounjaro® continue to dominate conversations around weight management and metabolic health, supplement companies are increasingly exploring ingredients that may support the […] Read More >>
Pet food innovation is moving quickly across the United States. From novel proteins and functional ingredients to fermentation-derived compounds and upcycled materials, manufacturers are continuing to develop increasingly sophisticated products […] Read More >>
Why this distinction matters more than ever For companies developing ingredients for the U.S. market, one question comes up early—and often: Should this ingredient go the GRAS route, or require […] Read More >>
Background On January 15, 2025, the FDA revoked authorization for FD&C Red No. 3 (erythrosine) for use in foods, including dietary supplements, and in ingested drugs. The agency followed a […] Read More >>
On June 2, 2025, the U.S. Food and Drug Administration (FDA) officially launched Elsa, a generative AI tool designed to assist FDA staff with core functions such as reviewing clinical […] Read More >>
A Generally Recognized as Safe (GRAS) or New Dietary Ingredient (NDI) notification is essential for novel food ingredient manufacturers and distributors to ensure that their product is recognized as safe […] Read More >>